Study S001445

Multicentre, Single-arm, Non-interventional Regulatory Post- Marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06283641
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 300
Start: 2024-04-08
Primary completion: 2025-01-13
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity
Interventions: DRUG:Liraglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1289-9747

Registered primary outcomes

Incidence of adverse events (AEs) by preferred term (PT) [From baseline (week 0) to week 26]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0002259	A multicenter real-world study on the safety and effectiveness of the glucagon-like peptide-1 receptor agonist (liraglutide) in adolescents with obesity in Taiwan. Chiu CF, Obesity research & clinical practice	2026	Nonrandomized study	PMID 42744726 DOI	cites ClinicalTrials.gov:NCT06283641
R0008690	Liraglutide in Adults With Obesity: A Multicentre, Single-Arm, Post-Marketing Surveillance Study in Taiwan. Tu ST, Endocrinology, diabetes & metabolism	2026	Nonrandomized study	PMID 42762462 DOI	cites ClinicalTrials.gov:NCT06283641